Thursday, 26 Apr 2018

You are here

NOR-SWITCH Study Validates Biosimilar Use in Multiple Indications

Lancet reports the results of the NOR-SWITCH study - a trial performed in Norway as biosimilars were being introduced. This study was designed to assess the efficacy and safety of transitioning from the originator (Remicade) to the less expensive biosimilar CT-P13 (Remsima/Inflectra) in the treatment of Crohn's disease, ulcerative colitis, spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and chronic plaque psoriasis.

NOR-SWITCH was a phase IV, 52 week, randomised, non-inferiority, double-blind trial with 52 weeks where 482 patients (previously on stable regimen of infliximab originator) randomised 1:1 to either continued infliximab originator or to CT-P13 treatment, with unchanged dosing regimen. The primary endpoint was disease worsening (according to different disease activity measures for each inflammatory condition) falling outside of the non-inferiority margin of 15%.

Most of the patients in the analysis set had Crohn's disease (32%), with fewer havng ulcerative colitis (19%), spondylitis (19%), RA (16%), PsA (6%) or psoriasis (7%).

Disease worsening occurred in 26% of the originator group and 30% of the biosimilar (CT-P13) group - thereby meeting the definition of noninferiority at 52 weeks. While the differences between drugs for those with Crohn's disease appeared to be near significant, they were not. Moreover, this trial was powered to assess noninferiority for all conditions combined and not individual disorders.Adverse events was similar between groups, including adverse events leading to discontinuation (4% vs. 3%).

The NOR-SWITCH trial will be one of the most cited trials as biosimilars are introduced in the US and worldwide. The data suggests that analytical proof of biosimilarity appears to be extrapolatable to the clinical indications afforded new biosimilars.

This trial is registered with ClinicalTrials.gov, number NCT02148640.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Favorable Certolizumab Safety Profile in Pregnancy

Clowse and colleagues have published an extensive review of the certolizumab pegol (CZP) in pregnancy database, and found no evidence that CZP has a teratogenic effect or contributes to fetal harm when compared to the general population. 

Severe Stevens-Johnson and Toxic Epidermal Necrolysis Syndromes May Respond to Etanercept

The Journal of Clinical Investigation reports the results of a trial wherein etanercept (ETN) was shown to be effective in treating cytotoxic T lymphocyte–mediated (CTL-mediated) severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).

Pediatric Use of TNF inhbitors Does Not Increase Malignancy Risk

A study of USA administrative claims data between 2000 to 2014 assessed the risk of cancer with exposure to tumour necrosis factor inhibitor (TNFi) in pediatric patients and found that TNFi therapy did not significantly increase the risk compared those not receiving TNFi.

Obesity Outweighs Psoriasis in Comorbidity Risk with Children

Like their adult counterparts, psoriasis in children is an independent risk factor for comorbidity, but not as much as  obesity.

Using claims data from Optum Laboratories Data Warehouse (150 million privately insured and Medicare enrollees), of 29 957 children with psoriasis were matched with a comparator cohort (children without psoriasis) and studied for the effects of psoriasis and obsesity. 

Anti-Drug Antibodies Partly Explain Secondary TNF Inhibitor Failures

An observational study of patients with active rheumatoid arthritis (RA) or spondyloarthritis (SpA) experiencing secondary failure to TNF inhibitor (TNFi) therapy showed that (secondary) loss of efficacy to a TNFi was associated with anti-drug antibodies in less than 30% of patients.